PASADENA, Calif., December 23, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company ...
Naturally, they’d like to see developer Arrowhead take the helm of the project to ensure that it stays as faithful to the source material as possible. Johan Pilestedt, the CCO of Arrowhead and ...